The aim of this study was to characterise the kinetics and durability of neutralizing antibody (Nab) response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the presence of hyperglycemia.
Robust neutralizing antibodies to SARS-CoV-2 develop and persist in subjects with diabetes and COVID-19 pneumonia / Dispinseri, Stefania; Lampasona, Vito; Secchi, Massimiliano; Cara, Andrea; Bazzigaluppi, Elena; Negri, Donatella; Brigatti, Cristina; Pirillo, Maria Franca; Marzinotto, Ilaria; Borghi, Martina; Rovere-Querini, Patrizia; Tresoldi, Cristina; Ciceri, Fabio; Scavini, Marina; Scarlatti, Gabriella; Piemonti, Lorenzo. - In: THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. - ISSN 0021-972X. - (2021). [Epub ahead of print] [10.1210/clinem/dgab055]
Robust neutralizing antibodies to SARS-CoV-2 develop and persist in subjects with diabetes and COVID-19 pneumonia
Marzinotto, Ilaria;Rovere-Querini, Patrizia;Ciceri, Fabio;Piemonti, Lorenzo
Ultimo
2021-01-01
Abstract
The aim of this study was to characterise the kinetics and durability of neutralizing antibody (Nab) response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the presence of hyperglycemia.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
